Now showing items 1674-1693 of 4640

    • Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development 

      Stratton, M (2008-04)
      We have developed a nonheuristic genome topography scan (GTS) algorithm to characterize the patterns of genomic alterations in human glioblastoma (GBM), identifying frequent p18(INK4C) and p16(INK4A) codeletion. Functional ...
    • Fever of Unknown Origin: the Value of FDG-PET/CT. 

      Kouijzer, IJE; Mulders-Manders, CM; Bleeker-Rovers, CP; Oyen, WJG (2018-03)
      Fever of unknown origin (FUO) is commonly defined as fever higher than 38.3°C on several occasions during at least 3 weeks with uncertain diagnosis after a number of obligatory investigations. The differential diagnosis ...
    • FFPE breast tumour blocks provide reliable sources of both germline and malignant DNA for investigation of genetic determinants of individual tumour responses to treatment. 

      Wilkins, A; Chauhan, R; Rust, A; Pearson, A; Daley, F; Manodoro, F; Fenwick, K; Bliss, J; Yarnold, J; Somaiah, N (2018-08)
      Background Bio-banked formalin-fixed paraffin-embedded (FFPE) tissues provide an excellent opportunity for translational genomic research. Historically matched blood has not always been collected as a source of germline ...
    • FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas. 

      Egbivwie, N; Cockle, JV; Humphries, M; Ismail, A; Esteves, F; Taylor, C; Karakoula, K; Morton, R; Warr, T; Short, SC; Brüning-Richardson, A (2019-01)
      The heterogeneous and invasive nature of pediatric gliomas poses significant treatment challenges, highlighting the importance of identifying novel chemotherapeutic targets. Recently, recurrent Fibroblast growth factor ...
    • Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas 

      Napolitano, A; Ostler, AE; Jones, RL; Huang, PH
      <jats:p>Sarcomas are a heterogeneous group of rare malignancies originating from mesenchymal tissues with limited therapeutic options. Recently, alterations in components of the fibroblast growth factor receptor (FGFR) ...
    • Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. 

      Martinez, VG; Pankova, V; Krasny, L; Singh, T; Makris, S; White, IJ; Benjamin, AC; Dertschnig, S; Horsnell, HL; Kriston-Vizi, J; Burden, JJ; Huang, PH; Tape, CJ; Acton, SE (2019-11)
      Lymph nodes (LNs) act as filters, constantly sampling peripheral cues. This is facilitated by the conduit network, a tubular structure of aligned extracellular matrix (ECM) fibrils ensheathed by fibroblastic reticular cells ...
    • Fiducial marker based intra-fraction motion assessment on cine-MR for MR-linac treatment of prostate cancer. 

      de Muinck Keizer, DM; Pathmanathan, AU; Andreychenko, A; Kerkmeijer, LGW; van der Voort van Zyp, JRN; Tree, AC; van den Berg, CAT; de Boer, JCJ (2019-04-04)
      We have developed a method to determine intrafraction motion of the prostate through automatic fiducial marker (FM) tracking on 3D cine-magnetic resonance (MR) images with high spatial and temporal resolution. Twenty-nine ...
    • Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. 

      Andtbacka, RHI; Collichio, F; Harrington, KJ; Middleton, MR; Downey, G; Ӧhrling, K; Kaufman, HL (2019-06-06)
      Background Talimogene laherparepvec is an oncolytic immunotherapy approved in the US, Europe, Australia and Switzerland. We report the final planned analysis of OPTiM, a randomized open-label phase III trial in patients ...
    • Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). 

      Darabi, H; Beesley, J; Droit, A; Kar, S; Nord, S; Moradi Marjaneh, M; Soucy, P; Michailidou, K; Ghoussaini, M; Fues Wahl, H; Bolla, MK; Wang, Q; Dennis, J; Alonso, MR; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Benitez, J; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Broeks, A; Brüning, T; Burwinkel, B; Chang-Claude, J; Choi, J-Y; Conroy, DM; Couch, FJ; Cox, A; Cross, SS; Czene, K; Devilee, P; Dörk, T; Easton, DF; Fasching, PA; Figueroa, J; Fletcher, O; Flyger, H; Galle, E; García-Closas, M; Giles, GG; Goldberg, MS; González-Neira, A; Guénel, P; Haiman, CA; Hallberg, E; Hamann, U; Hartman, M; Hollestelle, A; Hopper, JL; Ito, H; Jakubowska, A; Johnson, N; Kang, D; Khan, S; Kosma, V-M; Kriege, M; Kristensen, V; Lambrechts, D; Le Marchand, L; Lee, SC; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Margolin, S; Matsuo, K; Mayes, R; McKay, J; Meindl, A; Milne, RL; Muir, K; Neuhausen, SL; Nevanlinna, H; Olswold, C; Orr, N; Peterlongo, P; Pita, G; Pylkäs, K; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Seynaeve, C; Shah, M; Shen, C-Y; Shu, X-O; Southey, MC; Stram, DO; Surowy, H; Swerdlow, A; Teo, SH; Tessier, DC; Tomlinson, I; Torres, D; Truong, T; Vachon, CM; Vincent, D; Winqvist, R; Wu, AH; Wu, P-E; Yip, CH; Zheng, W; Pharoah, PDP; Hall, P; Edwards, SL; Simard, J; French, JD; Chenevix-Trench, G; Dunning, AM (2016-09-07)
      Genome-wide association studies have found SNPs at 17q22 to be associated with breast cancer risk. To identify potential causal variants related to breast cancer risk, we performed a high resolution fine-mapping analysis ...
    • Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. 

      Fachal, L; Aschard, H; Beesley, J; Barnes, DR; Allen, J; Kar, S; Pooley, KA; Dennis, J; Michailidou, K; Turman, C; Soucy, P; Lemaçon, A; Lush, M; Tyrer, JP; Ghoussaini, M; Moradi Marjaneh, M; Jiang, X; Agata, S; Aittomäki, K; Alonso, MR; Andrulis, IL; Anton-Culver, H; Antonenkova, NN; Arason, A; Arndt, V; Aronson, KJ; Arun, BK; Auber, B; Auer, PL; Azzollini, J; Balmaña, J; Barkardottir, RB; Barrowdale, D; Beeghly-Fadiel, A; Benitez, J; Bermisheva, M; Białkowska, K; Blanco, AM; Blomqvist, C; Blot, W; Bogdanova, NV; Bojesen, SE; Bolla, MK; Bonanni, B; Borg, A; Bosse, K; Brauch, H; Brenner, H; Briceno, I; Brock, IW; Brooks-Wilson, A; Brüning, T; Burwinkel, B; Buys, SS; Cai, Q; Caldés, T; Caligo, MA; Camp, NJ; Campbell, I; Canzian, F; Carroll, JS; Carter, BD; Castelao, JE; Chiquette, J; Christiansen, H; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Cornelissen, S; Couch, FJ; Cox, A; Cross, SS; Cybulski, C; Czene, K; Daly, MB; de la Hoya, M; Devilee, P; Diez, O; Ding, YC; Dite, GS; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Droit, A; Dubois, S; Dumont, M; Duran, M; Durcan, L; Dwek, M; Eccles, DM; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Fletcher, O; Floris, G; Flyger, H; Foretova, L; Foulkes, WD; Friedman, E; Fritschi, L; Frost, D; Gabrielson, M; Gago-Dominguez, M; Gambino, G; Ganz, PA; Gapstur, SM; Garber, J; García-Sáenz, JA; Gaudet, MM; Georgoulias, V; Giles, GG; Glendon, G; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Tibiletti, MG; Greene, MH; Grip, M; Gronwald, J; Grundy, A; Guénel, P; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hartikainen, JM; Hartman, M; He, W; Healey, CS; Heemskerk-Gerritsen, BAM; Heyworth, J; Hillemanns, P; Hogervorst, FBL; Hollestelle, A; Hooning, MJ; Hopper, JL; Howell, A; Huang, G; Hulick, PJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Isaacs, C; Iwasaki, M; Jager, A; Jakimovska, M; Jakubowska, A; James, PA; Janavicius, R; Jankowitz, RC; John, EM; Johnson, N; Jones, ME; Jukkola-Vuorinen, A; Jung, A; Kaaks, R; Kang, D; Kapoor, PM; Karlan, BY; Keeman, R; Kerin, MJ; Khusnutdinova, E; Kiiski, JI; Kirk, J; Kitahara, CM; Ko, Y-D; Konstantopoulou, I; Kosma, V-M; Koutros, S; Kubelka-Sabit, K; Kwong, A; Kyriacou, K; Laitman, Y; Lambrechts, D; Lee, E; Leslie, G; Lester, J; Lesueur, F; Lindblom, A; Lo, W-Y; Long, J; Lophatananon, A; Loud, JT; Lubiński, J; MacInnis, RJ; Maishman, T; Makalic, E; Mannermaa, A; Manoochehri, M; Manoukian, S; Margolin, S; Martinez, ME; Matsuo, K; Maurer, T; Mavroudis, D; Mayes, R; McGuffog, L; McLean, C; Mebirouk, N; Meindl, A; Miller, A; Miller, N; Montagna, M; Moreno, F; Muir, K; Mulligan, AM; Muñoz-Garzon, VM; Muranen, TA; Narod, SA; Nassir, R; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Neven, P; Nielsen, FC; Nikitina-Zake, L; Norman, A; Offit, K; Olah, E; Olopade, OI; Olsson, H; Orr, N; Osorio, A; Pankratz, VS; Papp, J; Park, SK; Park-Simon, T-W; Parsons, MT; Paul, J; Pedersen, IS; Peissel, B; Peshkin, B; Peterlongo, P; Peto, J; Plaseska-Karanfilska, D; Prajzendanc, K; Prentice, R; Presneau, N; Prokofyeva, D; Pujana, MA; Pylkäs, K; Radice, P; Ramus, SJ; Rantala, J; Rau-Murthy, R; Rennert, G; Risch, HA; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sánchez-Herrero, E; Sandler, DP; Santamariña, M; Saunders, C; Sawyer, EJ; Scheuner, MT; Schmidt, DF; Schmutzler, RK; Schneeweiss, A; Schoemaker, MJ; Schöttker, B; Schürmann, P; Scott, C; Scott, RJ; Senter, L; Seynaeve, CM; Shah, M; Sharma, P; Shen, C-Y; Shu, X-O; Singer, CF; Slavin, TP; Smichkoska, S; Southey, MC; Spinelli, JJ; Spurdle, AB; Stone, J; Stoppa-Lyonnet, D; Sutter, C; Swerdlow, AJ; Tamimi, RM; Tan, YY; Tapper, WJ; Taylor, JA; Teixeira, MR; Tengström, M; Teo, SH; Terry, MB; Teulé, A; Thomassen, M; Thull, DL; Tischkowitz, M; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Torres, D; Torres-Mejía, G; Troester, MA; Truong, T; Tung, N; Tzardi, M; Ulmer, H-U; Vachon, CM; van Asperen, CJ; van der Kolk, LE; van Rensburg, EJ; Vega, A; Viel, A; Vijai, J; Vogel, MJ; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wildiers, H; Winqvist, R; Wolk, A; Wu, AH; Yannoukakos, D; Zhang, Y; Zheng, W; Hunter, D; Pharoah, PDP; Chang-Claude, J; García-Closas, M; Schmidt, MK; Milne, RL; Kristensen, VN; French, JD; Edwards, SL; Antoniou, AC; Chenevix-Trench, G; Simard, J; Easton, DF; Kraft, P; Dunning, AM (2020-01-07)
      Genome-wide association studies have identified breast cancer risk variants in over 150 genomic regions, but the mechanisms underlying risk remain largely unknown. These regions were explored by combining association ...
    • Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. 

      Dadaev, T; Saunders, EJ; Newcombe, PJ; Anokian, E; Leongamornlert, DA; Brook, MN; Cieza-Borrella, C; Mijuskovic, M; Wakerell, S; Olama, AAA; Schumacher, FR; Berndt, SI; Benlloch, S; Ahmed, M; Goh, C; Sheng, X; Zhang, Z; Muir, K; Govindasami, K; Lophatananon, A; Stevens, VL; Gapstur, SM; Carter, BD; Tangen, CM; Goodman, P; Thompson, IM; Batra, J; Chambers, S; Moya, L; Clements, J; Horvath, L; Tilley, W; Risbridger, G; Gronberg, H; Aly, M; Nordström, T; Pharoah, P; Pashayan, N; Schleutker, J; Tammela, TLJ; Sipeky, C; Auvinen, A; Albanes, D; Weinstein, S; Wolk, A; Hakansson, N; West, C; Dunning, AM; Burnet, N; Mucci, L; Giovannucci, E; Andriole, G; Cussenot, O; Cancel-Tassin, G; Koutros, S; Freeman, LEB; Sorensen, KD; Orntoft, TF; Borre, M; Maehle, L; Grindedal, EM; Neal, DE; Donovan, JL; Hamdy, FC; Martin, RM; Travis, RC; Key, TJ; Hamilton, RJ; Fleshner, NE; Finelli, A; Ingles, SA; Stern, MC; Rosenstein, B; Kerns, S; Ostrer, H; Lu, Y-J; Zhang, H-W; Feng, N; Mao, X; Guo, X; Wang, G; Sun, Z; Giles, GG; Southey, MC; MacInnis, RJ; FitzGerald, LM; Kibel, AS; Drake, BF; Vega, A; Gómez-Caamaño, A; Fachal, L; Szulkin, R; Eklund, M; Kogevinas, M; Llorca, J; Castaño-Vinyals, G; Penney, KL; Stampfer, M; Park, JY; Sellers, TA; Lin, H-Y; Stanford, JL; Cybulski, C; Wokolorczyk, D; Lubinski, J; Ostrander, EA; Geybels, MS; Nordestgaard, BG; Nielsen, SF; Weisher, M; Bisbjerg, R; Røder, MA; Iversen, P; Brenner, H; Cuk, K; Holleczek, B; Maier, C; Luedeke, M; Schnoeller, T; Kim, J; Logothetis, CJ; John, EM; Teixeira, MR; Paulo, P; Cardoso, M; Neuhausen, SL; Steele, L; Ding, YC; De Ruyck, K; De Meerleer, G; Ost, P; Razack, A; Lim, J; Teo, S-H; Lin, DW; Newcomb, LF; Lessel, D; Gamulin, M; Kulis, T; Kaneva, R; Usmani, N; Slavov, C; Mitev, V; Parliament, M; Singhal, S; Claessens, F; Joniau, S; Van den Broeck, T; Larkin, S; Townsend, PA; Aukim-Hastie, C; Gago-Dominguez, M; Castelao, JE; Martinez, ME; Roobol, MJ; Jenster, G; van Schaik, RHN; Menegaux, F; Truong, T; Koudou, YA; Xu, J; Khaw, K-T; Cannon-Albright, L; Pandha, H; Michael, A; Kierzek, A; Thibodeau, SN; McDonnell, SK; Schaid, DJ; Lindstrom, S; Turman, C; Ma, J; Hunter, DJ; Riboli, E; Siddiq, A; Canzian, F; Kolonel, LN; Le Marchand, L; Hoover, RN; Machiela, MJ; Kraft, P; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Freedman, M; Wiklund, F; Chanock, S; Henderson, BE; Easton, DF; Haiman, CA; Eeles, RA; Conti, DV; Kote-Jarai, Z (2018-06-11)
      Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable ...
    • Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. 

      Horne, HN; Chung, CC; Zhang, H; Yu, K; Prokunina-Olsson, L; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Hopper, JL; Southey, MC; Schmidt, MK; Broeks, A; Muir, K; Lophatananon, A; Fasching, PA; Beckmann, MW; Fletcher, O; Johnson, N; Sawyer, EJ; Tomlinson, I; Burwinkel, B; Marme, F; Guénel, P; Truong, T; Bojesen, SE; Flyger, H; Benitez, J; González-Neira, A; Anton-Culver, H; Neuhausen, SL; Brenner, H; Arndt, V; Meindl, A; Schmutzler, RK; Brauch, H; Hamann, U; Nevanlinna, H; Khan, S; Matsuo, K; Iwata, H; Dörk, T; Bogdanova, NV; Lindblom, A; Margolin, S; Mannermaa, A; Kosma, V-M; Chenevix-Trench, G; kConFab/AOCS Investigators; Wu, AH; Ven den Berg, D; Smeets, A; Zhao, H; Chang-Claude, J; Rudolph, A; Radice, P; Barile, M; Couch, FJ; Vachon, C; Giles, GG; Milne, RL; Haiman, CA; Marchand, LL; Goldberg, MS; Teo, SH; Taib, NAM; Kristensen, V; Borresen-Dale, A-L; Zheng, W; Shrubsole, M; Winqvist, R; Jukkola-Vuorinen, A; Andrulis, IL; Knight, JA; Devilee, P; Seynaeve, C; García-Closas, M; Czene, K; Darabi, H; Hollestelle, A; Martens, JWM; Li, J; Lu, W; Shu, X-O; Cox, A; Cross, SS; Blot, W; Cai, Q; Shah, M; Luccarini, C; Baynes, C; Harrington, P; Kang, D; Choi, J-Y; Hartman, M; Chia, KS; Kabisch, M; Torres, D; Jakubowska, A; Lubinski, J; Sangrajrang, S; Brennan, P; Slager, S; Yannoukakos, D; Shen, C-Y; Hou, M-F; Swerdlow, A; Orr, N; Simard, J; Hall, P; Pharoah, PDP; Easton, DF; Chanock, SJ; Dunning, AM; Figueroa, JD (2016-01)
      The Cancer Genetic Markers of Susceptibility genome-wide association study (GWAS) originally identified a single nucleotide polymorphism (SNP) rs11249433 at 1p11.2 associated with breast cancer risk. To fine-map this locus, ...
    • Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. 

      Vigorito, E; Kuchenbaecker, KB; Beesley, J; Adlard, J; Agnarsson, BA; Andrulis, IL; Arun, BK; Barjhoux, L; Belotti, M; Benitez, J; Berger, A; Bojesen, A; Bonanni, B; Brewer, C; Caldes, T; Caligo, MA; Campbell, I; Chan, SB; Claes, KBM; Cohn, DE; Cook, J; Daly, MB; Damiola, F; Davidson, R; Pauw, AD; Delnatte, C; Diez, O; Domchek, SM; Dumont, M; Durda, K; Dworniczak, B; Easton, DF; Eccles, D; Edwinsdotter Ardnor, C; Eeles, R; Ejlertsen, B; Ellis, S; Evans, DG; Feliubadalo, L; Fostira, F; Foulkes, WD; Friedman, E; Frost, D; Gaddam, P; Ganz, PA; Garber, J; Garcia-Barberan, V; Gauthier-Villars, M; Gehrig, A; Gerdes, A-M; Giraud, S; Godwin, AK; Goldgar, DE; Hake, CR; Hansen, TVO; Healey, S; Hodgson, S; Hogervorst, FBL; Houdayer, C; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, A; Jacobs, L; Jakubowska, A; Janavicius, R; Jaworska-Bieniek, K; Jensen, UB; John, EM; Vijai, J; Karlan, BY; Kast, K; KConFab Investigators; Khan, S; Kwong, A; Laitman, Y; Lester, J; Lesueur, F; Liljegren, A; Lubinski, J; Mai, PL; Manoukian, S; Mazoyer, S; Meindl, A; Mensenkamp, AR; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Park, SK; Paulsson-Karlsson, Y; Pedersen, IS; Peissel, B; Peterlongo, P; Pfeiler, G; Phelan, CM; Piedmonte, M; Poppe, B; Pujana, MA; Radice, P; Rennert, G; Rodriguez, GC; Rookus, MA; Ross, EA; Schmutzler, RK; Simard, J; Singer, CF; Slavin, TP; Soucy, P; Southey, M; Steinemann, D; Stoppa-Lyonnet, D; Sukiennicki, G; Sutter, C; Szabo, CI; Tea, M-K; Teixeira, MR; Teo, S-H; Terry, MB; Thomassen, M; Tibiletti, MG; Tihomirova, L; Tognazzo, S; van Rensburg, EJ; Varesco, L; Varon-Mateeva, R; Vratimos, A; Weitzel, JN; McGuffog, L; Kirk, J; Toland, AE; Hamann, U; Lindor, N; Ramus, SJ; Greene, MH; Couch, FJ; Offit, K; Pharoah, PDP; Chenevix-Trench, G; Antoniou, AC (2016-01)
      Population-based genome wide association studies have identified a locus at 9p22.2 associated with ovarian cancer risk, which also modifies ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. We conducted fine-scale ...
    • Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. 

      Shi, J; Zhang, Y; Zheng, W; Michailidou, K; Ghoussaini, M; Bolla, MK; Wang, Q; Dennis, J; Lush, M; Milne, RL; Shu, X-O; Beesley, J; Kar, S; Andrulis, IL; Anton-Culver, H; Arndt, V; Beckmann, MW; Zhao, Z; Guo, X; Benitez, J; Beeghly-Fadiel, A; Blot, W; Bogdanova, NV; Bojesen, SE; Brauch, H; Brenner, H; Brinton, L; Broeks, A; Brüning, T; Burwinkel, B; Cai, H; Canisius, S; Chang-Claude, J; Choi, J-Y; Couch, FJ; Cox, A; Cross, SS; Czene, K; Darabi, H; Devilee, P; Droit, A; Dork, T; Fasching, PA; Fletcher, O; Flyger, H; Fostira, F; Gaborieau, V; García-Closas, M; Giles, GG; Mervi Grip; Guenel, P; Haiman, CA; Hamann, U; Hartman, M; Miao, H; Hollestelle, A; Hopper, JL; Hsiung, C-N; kConFab Investigators; Ito, H; Jakubowska, A; Johnson, N; Torres, D; Kabisch, M; Kang, D; Khan, S; Knight, JA; Kosma, V-M; Lambrechts, D; Li, J; Lindblom, A; Lophatananon, A; Lubinski, J; Mannermaa, A; Manoukian, S; Le Marchand, L; Margolin, S; Marme, F; Matsuo, K; McLean, C; Meindl, A; Muir, K; Neuhausen, SL; Nevanlinna, H; Nord, S; Børresen-Dale, A-L; Olson, JE; Orr, N; van den Ouweland, AMW; Peterlongo, P; Putti, TC; Rudolph, A; Sangrajrang, S; Sawyer, EJ; Schmidt, MK; Schmutzler, RK; Shen, C-Y; Hou, M-F; Shrubsole, MJ; Southey, MC; Swerdlow, A; Teo, SH; Thienpont, B; Toland, AE; Tollenaar, RAEM; Tomlinson, I; Truong, T; Tseng, C-C; Wen, W; Winqvist, R; Wu, AH; Yip, CH; Zamora, PM; Zheng, Y; Floris, G; Cheng, C-Y; Hooning, MJ; Martens, JWM; Seynaeve, C; Kristensen, VN; Hall, P; Pharoah, PDP; Simard, J; Chenevix-Trench, G; Dunning, AM; Antoniou, AC; Easton, DF; Cai, Q; Long, J (2016-09)
      Previous genome-wide association studies among women of European ancestry identified two independent breast cancer susceptibility loci represented by single nucleotide polymorphisms (SNPs) rs13281615 and rs11780156 at 8q24. ...
    • First evaluation of the feasibility of MLC tracking using ultrasound motion estimation. 

      Fast, MF; O'Shea, TP; Nill, S; Oelfke, U; Harris, EJ (2016-08)
      Purpose To quantify the performance of the Clarity ultrasound (US) imaging system (Elekta AB, Stockholm, Sweden) for real-time dynamic multileaf collimator (MLC) tracking.Methods The Clarity calibration and quality assurance ...
    • First report on the reliability and validity of speech handicap index in native English-speaking patients with head and neck cancer. 

      Dwivedi, RC; St Rose, S; Roe, JWG; Chisholm, E; Elmiyeh, B; Nutting, CM; Clarke, PM; Kerawala, CJ; Rhys-Evans, PH; Harrington, KJ; Kazi, R (2011-03)
      Background Posttreatment speech problems are seen in nearly half of patients with head and neck cancer. Although there are many voice-specific scales, surprisingly there is no speech-specific questionnaire for English-speaking ...
    • First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. 

      Basu, B; Dean, E; Puglisi, M; Greystoke, A; Ong, M; Burke, W; Cavallin, M; Bigley, G; Womack, C; Harrington, EA; Green, S; Oelmann, E; de Bono, JS; Ranson, M; Banerji, U (2015-08)
      Purpose AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models.Experimental design A rolling six-dose escalation was performed to define ...
    • First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. 

      Sessa, C; Shapiro, GI; Bhalla, KN; Britten, C; Jacks, KS; Mita, M; Papadimitrakopoulou, V; Pluard, T; Samuel, TA; Akimov, M; Quadt, C; Fernandez-Ibarra, C; Lu, H; Bailey, S; Chica, S; Banerji, U (2013-07)
      Purpose A phase I study was conducted with the primary objective of determining the maximum tolerated dose (MTD) of AUY922 in patients with advanced solid tumors. Secondary objectives included characterization of the safety, ...
    • First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors. 

      Shimomura, A; Yamamoto, N; Kondo, S; Fujiwara, Y; Suzuki, S; Yanagitani, N; Horiike, A; Kitazono, S; Ohyanagi, F; Doi, T; Kuboki, Y; Kawazoe, A; Shitara, K; Ohno, I; Banerji, U; Sundar, R; Ohkubo, S; Calleja, EM; Nishio, M (2019-03)
      HSP90 is involved in stability and function of cancer-related proteins. This study was conducted to define the MTD, safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy of TAS-116, a novel class, ...